Research is ongoing to improve the efficacy and safety of antineoplastic antibiotics. New formulations, such as liposomal doxorubicin, have been developed to reduce toxicity. Additionally, efforts are being made to identify biomarkers that can predict response to these drugs, allowing for more personalized treatment approaches. Combination therapies that include antineoplastic antibiotics and novel agents are also being explored to overcome resistance and enhance treatment outcomes.
